ArticleEuropean journal of medical research2025
MRI quantitative imaging biomarkers in differentiating brain parenchymal tuberculoma and lung cancer brain metastases.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBrain parenchymal tuberculoma (BT) and brain metastases (BM) originating from lung cancer often exhibit overlapping clinical and imaging features, making accurate differentiation challenging. Current diagnostic approaches remain suboptimal. PURPOSE: This study aimed to develop a radiomics-based MRI model to differentiate BT from BM and enhance model interpretability using Shapley Additive Explanations (SHAP) analysis. MATERIAL AND
methodsThis retrospective study involved 175 patients (97 with BT and 78 with BM) treated at Hangzhou Red Cross Hospital from January 2018 to March 2024, encompassing 1014 lesions (581 in BT and 433 in BM). Patients were randomly divided into training (n = 122) and test sets (n = 53) in a 7:3 ratio. MRI images were segmented and preprocessed for radiomics feature extraction. Feature selection was performed using recursive feature elimination. Logistic regression models were developed based on features from contrast-enhanced T1-weighted imaging (T1WI+C) and fluid-attenuated inversion recovery (FLAIR) sequences. Three predictive models were assessed using the area under the receiver operating characteristic curve (AUC): the optimal radiomics model, a combined clinical-radiological model, and an integrated radiomics and multi-clinical model (RMCM).
resultsFollowing feature selection, the FLAIR and T1WI+C models retained six and four essential radiomic features, respectively. At the lesion level, the T1WI+C model achieved superior performance (AUC: 0.932 in the training set; 0.933 in the test set) compared to the FLAIR model (AUC: 0.824 and 0.869, respectively). At the patient level, the RMCM, incorporating eight clinical-radiological features such as CEA, age, and peritumoral edema, showed superior diagnostic performance (AUC: 0.986 in training; 0.958 in testing). SHAP analysis highlighted the radiomics score as the key contributor to its diagnostic value.
conclusionsA radiomics model based on T1WI+C MRI sequences effectively distinguishes BT from BM. Incorporating clinical and radiological features into the RMCM further improves diagnostic accuracy, offering a robust, interpretable tool to aid clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.